

Wellnex Life Limited (ASX/AIM: WNX)

Appendix 4E – Preliminary Final Report FY2025 (unaudited)

Investment Highlights

- Total revenue for the 12 months to 30 June 2025 ("FY25") was \$23.6 million, an increase of 40.4% compared to the prior comparative period ("PCP") (12 months to 30 June 2024 ("FY24"): \$16.8 million). An order for a further \$0.3m revenue was delivered in the period, though received on 1 July 2025, immediately after the period end.
- Gross profit for FY25 was \$6.9 million, an increase of 38% compared to PCP (FY24: \$5.0 million)
- EBITDA loss for FY25 was up 13.63% to \$11.6 million compared to PCP (FY24: \$10.6 million loss) impacted by one off non-cash expenses of \$8.6 million and one off transaction and corporate fees of \$3.1 million.
- Normalised EBITDA loss of \$2.2 million for FY25, improving by 57.0% compared to PCP (FY24: \$5.2 million loss)
- Net Assets as at 30 June 2025 were \$11.3 million, an increase of 85.6% compared to PCP (FY24: \$6.1 million)

Wellnex Life Limited (ASX) ("Wellnex Life" or the "Company") is pleased to release its Appendix 4E for Financial Year 2025 (**FY25**).

In FY25, Wellnex Life achieved continued revenue and margin growth whilst further establishing a platform for future prosperity with the successful dual listing on the AIM market of the London Stock Exchange. This allowed the Company to strengthen its balance sheet with the settlement of the deferred consideration for Pain Away and the convertible note saving the company c.\$1.4 million in annual costs.

Total revenue for FY25 was \$23.6 million which was an increase of 40.4% from PCP (FY24: \$16.8 million), with the increase in revenue primarily achieved from Wellnex Life's brands, including Pain Away.

The Company also saw a rise in gross profit in dollar terms of 38.4% to \$6.9 million (FY24: \$5.0 million) which was in line with FY24 as a percentage of revenue. This was despite a one-off increase in trade investment in 1HFY25 which resulted in gross margin decreasing to 23% with a more disciplined approach to trade investment in the 2HFY25 increasing gross margin for this period to 37%.

Total loss for FY25 was \$15.6 million, which was impacted by non-cash and one-off expenses of \$11.7 million, primarily in relation to Pain Away and other corporate activities including the dual listing on the AIM market of the London Stock Exchange. The normalised EBITDA loss for FY25 decreased by 57.0% to \$2.2 million compared to PCP (FY24: \$5.2 million loss).

	FY24 (\$'000)	FY25 (\$'000)	% Change
Total Revenue	16,828	23,625	40.4%
Gross Profit	4,969	6,879	38.4%
NPAT	(13,739)	(15,604)	13.6%
Adjustments			
Depreciation	774	1,379	
Finance Cost	2,395	2,627	
EBITDA	(10,570)	(11,597)	
Adjustments			
Share Based Payment	491	4,189	
Impairments	4,445	1,482	

WELLNEX

Transaction Costs	1,112	3,636	
Net Gain on CN	(663)	61	
Normalised EBITDA	(5,185)	(2,229)	

The total net assets of the entity at 30 June 2025 were \$11.3 million as increase of 85.6% compared to the PCP (at 30 June 2024: \$6.1 million.)

In FY26 Wellnex Life has many growth initiatives that will continue to drive revenue growth and build strong margins and will look to continue expanding its licensing opportunities domestically and internationally.

This announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)

Zack Bozinovski

Chief Executive Officer

P: +61 3 8399 9419

E: zack.b@wellnexlife.com.au

UK Investors

Reach Markets

T: 1300 805 941

E: IR@reachmarkets.com.au

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson / Robert Collins Tel: +44 (0) 20 7409 3494

Orana Corporate LLP (Joint Broker)

swykeham@oranacorp.com

Sebastian Wykeham

S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

About Wellnex Life

Wellnex Life Limited (ASX/AIM:WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing on ASX in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major



pharmaceutical companies in Australia and globally that have given the Company's registered products a distribution channel with a steadily increasing global geographic footprint.

In December 2023, Wellnex Life acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.Wellnex Lifelife.com.au/

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.